Combination therapy with Renin-Angiotensin-aldosterone receptor blockers for hypertension: how far have we come?

Area of Science:

• Cardiology
• Pharmacology
• Nephrology

Background:

• Many patients with hypertension require multiple antihypertensive medications to reach blood pressure goals.
• Early achievement of blood pressure targets is linked to reduced cardiovascular events.
• Fixed-dose combination therapy is an established strategy to improve medication adherence.

Purpose of the Study:

• To review the rationale and evidence for initial combination therapy in hypertension management.
• To discuss the role of renin-angiotensin-aldosterone system (RAAS) blockers in combination therapies.
• To highlight ongoing research comparing different initial combination regimens.

Main Methods:

• Review of clinical trials and studies on antihypertensive combination therapy.
• Analysis of the benefits of specific drug classes, including RAAS blockers, diuretics, and calcium channel blockers.
• Examination of fixed-dose combination products and their efficacy.

Main Results:

• Combination therapy, especially with RAAS blockers, is frequently necessary for hypertension control.
• Thiazide diuretics are often required alongside RAAS blockers to achieve target blood pressure.
• Calcium channel blockers are also used in combination with ACE inhibitors.

Conclusions:

• Initial combination therapy is a valid strategy for achieving blood pressure goals and potentially reducing cardiovascular risk.
• The combination of RAAS blockers with diuretics or calcium channel blockers are common approaches.
• Further studies are needed to compare the relative benefits of RAAS blocker/diuretic versus RAAS blocker/calcium channel blocker initial therapy.